Capital International Investors Acquires New Shares in NewAmsterdam Pharma (NASDAQ:NAMS)

Capital International Investors purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,062,535 shares of the company's stock, valued at approximately $53,007,000. Capital International Investors owned 2.23% of NewAmsterdam Pharma as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in NAMS. Jennison Associates LLC increased its stake in shares of NewAmsterdam Pharma by 291.9% during the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company's stock valued at $102,763,000 after acquiring an additional 2,978,263 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of NewAmsterdam Pharma by 2,410.4% in the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock valued at $59,499,000 after purchasing an additional 2,222,900 shares during the last quarter. Alliancebernstein L.P. purchased a new stake in shares of NewAmsterdam Pharma during the 4th quarter valued at $47,752,000. TimesSquare Capital Management LLC increased its holdings in shares of NewAmsterdam Pharma by 250.9% during the 4th quarter. TimesSquare Capital Management LLC now owns 895,574 shares of the company's stock worth $23,016,000 after buying an additional 640,329 shares during the last quarter. Finally, American Century Companies Inc. purchased a new position in shares of NewAmsterdam Pharma in the 4th quarter worth $8,907,000. Institutional investors and hedge funds own 89.89% of the company's stock.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock traded up $0.08 during midday trading on Friday, hitting $17.55. 344,493 shares of the stock were exchanged, compared to its average volume of 915,342. NewAmsterdam Pharma has a 1 year low of $14.06 and a 1 year high of $27.29. The firm has a market cap of $1.93 billion, a P/E ratio of -6.75 and a beta of -0.01. The company has a 50 day moving average price of $19.66 and a two-hundred day moving average price of $21.20.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million. As a group, analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the transaction, the chief accounting officer now owns 15,000 shares in the company, valued at approximately $305,550. This trade represents a 90.91 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James N. Topper purchased 1,135 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The shares were purchased at an average cost of $22.49 per share, for a total transaction of $25,526.15. Following the completion of the transaction, the director now owns 3,013,569 shares in the company, valued at approximately $67,775,166.81. This represents a 0.04 % increase in their position. The disclosure for this purchase can be found here. 19.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a research report on Monday, March 3rd. Royal Bank of Canada restated an "outperform" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Needham & Company LLC reiterated a "buy" rating and set a $42.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, April 8th. Scotiabank raised their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Thursday, February 27th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $43.33.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.